Titan Pharmaceuticals (NSDQ:TTNP) and Braeburn Pharmaceuticals said today that they plan to end a 2012 licensing agreement that gave Braeburn exclusive rights to commercialize Probuphine in the U.S. and Canada.
Probuphine, which was developed using Titan’s ProNeura continuous drug-delivery tech, is an implant that can be placed in a patient’s upper arm in an outpatient office procedure. The FDA approved Probuphine in May 2016 to deliver buprenorphine as a long-term maintenance treatment for people suffering from opioid addiction.
Get the full story at our sister site, Drug Delivery Business News.